Aktuelle wissenschaftliche Publikationen aus der Klinik

Neueste Publikationen der Arbeitsgruppe von Prof. Schulze-Bergkamen mit dem NCT Heidelberg
(in der international führenden Fachzeitschrift für Magen-Darm-Erkrankungen) Gastroenterologie

Mcl1 is required for maintenance of intestinal homeostasis and prevention of carcinogenesis in mice. Healy ME, Boege Y, …, Schulze-Bergkamen H, …., Weber M. Gastroenterology 2020 159(1):183-199.

Nuclear Translocation of RELB is Increased in Diseased Human Liver and Promotes Ductular Reaction and Biliary Fibrosis in Mice.Elßner C, Goeppert B, Longerich T, Scherr AL, Stindt J, Nanduri LK, Rupp C, Kather JN, Schmitt N, Kautz N, Breuhahn K, Ismail L, Heide D, Hetzer J, García-Beccaria M, Hövelmeyer N, Waisman A, Urbanik T, Mueller S, Gdynia G, Banales JM, Roessler S, Schirmacher P, Jäger D, Schölch S, Keitel V, Heikenwalder M, Schulze-Bergkamen H, Köhler BC., Gastroenterology. 2018 Nov 13. pii: S0016-5085(18)35260-0

Zum Thema Magen und Speiseröhrenkrebs:

A mulitcentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Türeci O, Sahin U, Schulze-Bergkamen H et al. Ann Oncol 2019; 30(9):1487-1495.

Zum Thema Brustkrebs:

Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer. Vallet S, … Schulze-Bergkamen H, … Jäger D, Podar K. Breast Cancer Res Treat. 2019; 173(3):585-596.

Zum Thema Leberzellkrebs:
Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression. Apostolidis L, Pfeiffenberger J, Gotthardt D, Radeleff B, Mehrabi A, Schemmer P, Jäger D, Schirmacher P, Stremmel W, Schulze-Bergkamen H, Springfeld C, Weiss KH. Gastrointest Tumors. 2018 Sep;5(1-2):38-46

Zum Thema Gallenwegskrebs:
An undifferentiated carcinoma at Klatskin-position with long-term complete remission after chemotherapy. Köhler BC, Goeppert B, Waldburger N, Schlamp K, Sauer P, Jäger D, Weiss KH, Macher-Göppinger S, Schulze-Bergkamen H, Schirmacher P, Springfeld C., Oncotarget. 2018 Apr 24;9(31):22230-22235.

Prolyl hydroxylase 3 attenuates MCL-1-mediated ATP production to suppress the metastatic potential of colorectal cancer cells. Radhakrishnan P, Ruh N, Harnoss JM, Kiss J, Mollenhauer M, Scherr AL, Platzer LK, Schmidt T, Podar K, Opferman JT, Weitz J, Schulze-Bergkamen H, Koehler BC, Ulrich A, Schneider. MCancer Res. 2016 Feb 26.

Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications. Bashari MH, Fan F, Vallet S, Sattler M, Arn M, Luckner-Minden C, Schulze-Bergkamen H, Zörnig I, Marme F, Schneeweiss A, Cardone MH, Opferman JT, Jäger D, Podar K. Breast Cancer Res. 2016 Feb 26;18(1):26.

Low levels of Caspase-3 predict favourable response to 5FU-based chemotherapy in advanced colorectal cancer: Caspase-3 inhibition as a therapeutic approach. Flanagan L, Meyer M, Fay J, Curry S, Bacon O, Duessmann H, John K, Boland KC, McNamara DA, Kay EW, Bantel H, Schulze-Bergkamen H, Prehn JH. Cell Death Dis. 2016 Feb 4

Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signaling. Koehler BC, Jassowicz A, Scherr AL, Lorenz S, Radhakrishnan P, Kautz N, Elssner C, Weiss J, Jaeger D, Schneider M, Schulze-Bergkamen H. BMC Cancer. 2015 Nov 19;15:919

Hepatobiliary malignancies in Wilson disease. Pfeiffenberger J, Mogler C, Gotthardt DN, Schulze-Bergkamen H, Litwin T, Reuner U, Hefter H, Huster D, Schemmer P, Czlonkowska A, Schirmacher P, Stremmel W, Cassiman D, Weiss KH. Liver Int. 2015 May;35(5):1615.

Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients. Weinmann A, Koch S, Sprinzl M, Kloeckner R, Schulze-Bergkamen H, Düber C, Lang H, Otto G, Wörns MA, Galle PR. Liver Int. 2015 Feb;35(2):591-600.

Predictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patients. Weinmann A, Sattler T, Unold HP, Grambihler A, Teufel A, Koch S, Schuchmann M, Biesterfeld S, Wörns MA, Galle PR, Schulze-Bergkamen H. J Clin Gastroenterol. 2015 May-Jun;49(5):438-47

Activation of SIRT1 by human chorionic gonadotropin exerts a therapeutic effect on hepatic injury and inflammation. Hepatology. 2017 [Epub ahead of print].Steinmetz C, Kashyap A, Zhivkova N, Alizor H, Ernst I, Gottfried-Brand D, Janssen H, Teufel A, Schulze-Bergkamen H, Lotz J, Kuball J, Theobald M, Otto G, Lang H, Galle PR, Strand D, Strand S.

Possible Mechanisms of Ethanol-Mediated Colorectal Carcinogenesis: The Role of Cytochrome P4502E1, Etheno-DNA Adducts, and the Anti-Apoptotic Protein Mcl-1. Koehler BC, Arslic-Schmitt T, Peccerella T, Scherr AL, Schulze-Bergkamen H, Bruckner T, Gdynia G, Jäger D, Mueller S, Bartsch H, Seitz HK. Alcohol Clin Exp Res. 2016 [Epub ahead of print]

Bcl-xL is an oncogenic driver in colorectal cancer. Scherr AL, Gdynia G, Salou M, Radhakrishnan P, Duglova K, Heller A, Keim S, Kautz N, Jassowicz A, Elssner C, He YW, Jäger D, Heikenwälder M, Schneider M, Weber A, Roth W, Schulze-Bergkamen H, Köhler. Cell Death and Disease 2016; 18;7(8):e2342.

A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer Development. Boege Y, Malehmir M, Healy ME, …, Schulze-Bergkamen H, …, Weber A. Cancer Cell. 2017 Sep 11;32(3):342-359.

Liver cancers with stem/progenitor-cell features - a rare chemotherapy-sensitive malignancy. Köhler BC, Waldburger N, Schlamp K, Jäger D, Weiss KH, Schulze-Bergkamen H, Schirmacher P, Springfeld C. Oncotarget. 2017 Jun 5;8(35):59991-59998.

Outcome Results of Treatment with Selective Internal Radiation Therapy (SIRT) in Patients with Hepatocellular Carcinoma: A Single Center Experience. Pfeiffenberger J, Zimmermann T, Gotthardt DN, Springfeld C, Stremmel W, Schirmacher P, Schulze-Bergkamen H, Mehrabi A, Michalski CW, Hoffmann K, Kortes N, Radeleff B, Haberkorn U, Kratochwil C, Weiss KH, Grüllich C. Journal of Cancer Therapy 2017; 8:349-359.

Possible Mechanisms of Ethanol-Mediated Colorectal Carcinogenesis: The Role of Cytochrome P4502E1, Etheno-DNA Adducts, and the Anti-Apoptotic Protein Mcl-1. Alcohol Clin Exp Res 2016; 40(10):2094-2101. Koehler BC, Arslic-Schmitt T, Peccerella T, Scherr AL, Schulze-Bergkamen H, Bruckner T, Gdynia G, Jäger D, Mueller S, Bartsch H, Seitz HK.  

Weitere ausgewählte Publikationen als Erst- oder Letztautor

Unresectable isolated hepatic metastases from solid pseudopapillary neoplasm of the pancreas: a case report of chemosaturation with high-dose melphalan. Hofmann H, von Haken R, Werner J, Kortes N, Bergmann F, Schemmer P, Jäger D, Radeleff B, Schulze-Bergkamen H. Pancreatology. 2014 Nov-Dec;14(6):546-9

Targeting cell death signaling in colorectal cancer – current strategies and future perspectives. Koehler BC, Jaeger D, Schulze-Bergkamen H. World Journal of Gastroenterology 2014; 20(8):1923-34.

Nuclear expression of the deubiquitinase CYLD is associated with improved survival in human hepatocellular carcinoma. Welte S, Urbanik T, Koehler BC, Lorenzo Bermejo J, Pinna F, Weiss KH, Schemmer P, Jaeger D, Longerich T, Breuhahn K, Schulze-Bergkamen H. PLoS One. 2014; 9(10):e110591.

Pan-Bcl-2 inhibitor Obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells. Koehler BC, Scherr AL, Lorenz S, Elssner C, Kautz N, Welte S, Jaeger D, Urbanik T, Schulze-Bergkamen H. PloS One. 2014; 9(9):e106571.

CYLD deletion triggers nuclear factor-kB-signaling and increases cell death resistance in murine hepatocytes. Urbanik T, Koehler BC, Wolpert L, Elssner C, Scherr AL, Longerich T, Kautz N, Welte S, Hoevelmeyer N, Jaeger D, Waisman A, Schulze-Bergkamen H. World J  Gastroenterol. 2014; 20(45):17049-64.

Beyond cell death – Antiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitro. Koehler BC, Scherr AL, Lorenz S, Urbanik T, Kautz N, Elssner C, Welte S, Jäger D, Schulze-Bergkamen H. PLOS One 2013; 8(10):e76446.

Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice. Urbanik T, Boger RJ, Longerich T, Becker K, Ehrenberg KR, Hövelmeyer N, Hahn M, Schuchmann M, Jäger D, Waisman A, Wörns MA, Schulze-Bergkamen H. Journal of Hepatology 2012; 57:995-1003. Editorial: Gautheron J, Luedde T. A novel player in inflammation and cancer: The deubiquitinase CYLD controls HCC development. Journal of Hepatology 2012; 57(5):937-9.

Hepatocyte-specific deletion of the anti-apoptotic protein Mcl-1 triggers proliferation and hepatocarcinogenesis in mice. Weber A, Boger RJ, Vick B, Urbanik T, Haybaeck J, Zoller S, Teufel A, Krammer PH, Opferman JT, Galle PR, Heikenwalder M, Schuchmann M, Schulze-Bergkamen H. Hepatology 2010; 51(4):1226-1236. Editorial: Jost PJ, Kaufmann T. Cancer caused by too much apoptosis – an intriguing contradiction? Hepatology 2010; 51:1110-1112

Knock-out of Myeloid cell leukaemia-1 induces profound liver damage and increases apoptosis susceptibility of murine hepatocytes. Vick B, Weber A, Urbanik T, Krammer PH, Opferman JT, Schuchmann M, Galle PR, Schulze-Bergkamen H. Hepatology 2009; 49(2):627-36.

Novel ways to sensitize gastrointestinal cancer to apoptosis. Schulze-Bergkamen H, Weinmann A, Möhler M, Siebler J, Galle PR. Gut 2009; 58(7):1010-24.

Hepatocyte Growth Factor induces Mcl-1 in primary human hepatocytes and inhibits CD95-mediated apoptosis via Akt. Schulze-Bergkamen H, Brenner D, Krueger A, Suess D, Fas SC, Frey CR, Dax A, Zink D, Büchler P, Müller M, Krammer PH. Hepatology 2004; 39:645-654.

Primary human hepatocytes – a valuable tool for investigation of apoptosis and hepatitis B virus infection. Schulze-Bergkamen H, Untergasser A, Dax A, Vogel H, Büchler P, Klar E, Lehnert T, Friess H, Büchler MW, Kirschfink M, Stremmel W, Krammer PH, Müller M, Protzer U. Journal of Hepatology 2003; 38(6):736-744.